Filing summary
Issuer and period: The supplied filing is Onconova Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2013—not a filing identified as Traws Pharma, Inc. The issuer discrepancy should be verified before relying on this summary.
Business context and reporting period
Onconova was a clinical-stage biopharmaceutical company developing cancer treatments. Its lead candidate, rigosertib, was in Phase 2 and Phase 3 trials; its other programs included ON 013105, recilisib, and six preclinical programs. The financial statements consolidate the company and its wholly owned European subsidiary.
Financial performance and position
| Metric | Three months ended June 30, 2013 | Six months ended June 30, 2013 | Comparable 2012 period |
|---|---|---|---|
| Revenue | $0.591 million | $1.707 million | $0.220 million quarterly; $0.418 million half-year |
| Research and development expense | $10.047 million | $22.803 million | $6.776 million quarterly; $15.224 million half-year |
| General and administrative expense | $3.117 million | $6.463 million | $1.627 million quarterly; $4.087 million half-year |
| Net loss | $12.562 million | $27.407 million | $7.416 million quarterly; $18.215 million half-year |
| Net loss applicable to common stockholders | $13.594 million | $29.458 million | $8.343 million quarterly; $20.373 million half-year |
| Operating cash used | Not presented quarterly | $29.884 million | $12.247 million half-year |
At June 30, 2013, cash and cash equivalents were $51.181 million, current assets $57.048 million, current liabilities $13.307 million, and working capital approximately $43.7 million. Total assets were $57.914 million and total liabilities $27.490 million. The balance sheet reported no conventional borrowings at quarter-end; deferred revenue was $17.645 million in total. The company had an accumulated deficit of $195.760 million and stockholders’ deficit of $172.942 million. Operating margins were negative, reflecting operating losses; the filing does not present a margin percentage.
Changes versus prior comparable periods
- Second-quarter revenue increased $0.371 million year over year; first-half revenue rose $1.289 million, primarily reflecting the Baxter collaboration, partly offset by reduced research funding.
- First-half R&D expense increased $7.579 million, driven mainly by higher clinical-trial costs, staffing, and consulting. G&A increased $2.376 million.
- First-half net loss widened by $9.192 million. Cash used in operations increased to $29.884 million from $12.247 million, and cash declined $30.346 million during the first half.
- In April 2013, the company changed the treatment of outstanding stock options following revisions to option-holder liquidity transactions. It reclassified $14.482 million of option liability to additional paid-in capital; this was a significant accounting and equity presentation item.
Outlook, risks, and unusual items
- Management expected ongoing operating losses and higher near-term spending on rigosertib trials and other development programs. It expected the lead Phase 3 higher-risk MDS trial’s top-line overall survival results in Q4 2013 or Q1 2014.
- After quarter-end, the company completed its July 30, 2013 IPO, raising $79.6 million net from 5,941,667 shares sold at $15 each. All preferred shares converted to common stock immediately before the offering. Management said cash on hand plus IPO proceeds should fund operations for at least 12 months, while anticipating a need for substantial additional financing in the future.
- The company reported no material legal proceedings and no material non-cancelable purchase commitments. It remained dependent on financing, clinical and regulatory outcomes, collaboration partners, and third-party research and manufacturing providers.
- Baxter’s European rigosertib agreement included a $50 million upfront payment and potentially substantial development, regulatory, and sales milestones and royalties; these future payments depend on specified events and are not assured. SymBio also had milestone and royalty arrangements for Japan and Korea.
- Management concluded disclosure controls were not effective as of June 30, 2013 because of an unremediated material weakness involving insufficient accounting and financial-reporting staff with appropriate GAAP and SEC reporting experience.
Most important facts for an investor to verify
- Confirm the filing is relevant to the intended company: the document names Onconova Therapeutics, Inc., not Traws Pharma, Inc.
- Check the current status and results of rigosertib’s clinical trials, particularly the anticipated higher-risk MDS Phase 3 readout.
- Review cash burn and runway using the post-IPO capital raise, and distinguish management’s at-least-12-month estimate from the company’s stated longer-term need for further financing.
- Verify whether the accounting-control material weakness was remediated and whether subsequent filings reported any additional control issues.
- Assess the terms, progress, and termination status of the Baxter and SymBio collaborations; do not treat contingent milestones or royalties as committed revenue.